1049731-01-2Relevant articles and documents
CF3-Inspired Synthesis of Air-Tolerant 9-Phosphaanthracenes that Feature Fluorescence and Crystalline Polymorphs
Ito, Shigekazu,Koshino, Kota,Mikami, Koichi
, p. 830 - 837 (2018)
9-Phosphaanthracene (dibenzo[b,e]phosphorin, acridophosphine) has attracted interest as one of the heavier acenes. Herein, we demonstrate an efficient synthetic process that provides air-tolerant 1,8-bis(trifluoromethyl)-9-phosphaanthracenes. The sterically encumbered and electron-withdrawing trifluoromethyl (CF3) groups are quite advantageous not only to stabilize the intrinsically unstable heavier unsaturated phosphorus atom but also to facilitate construction of the phosphinine skeleton based on a putative increase in aromaticity. The isolated 9-phosphaanthracenes allowed characterization of their fluorescence functionality and planar heteroanthracene frameworks. The crystal structures of 9-phosphaanthracenes are remarkably dependent on the aryl substituents at the 10 position; anthryl-substituted 9-phosphaanthracene showed unique polymorphs that induced different-colored crystals.
NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS
-
Paragraph 0186, (2013/11/06)
The present invention relates to compounds of general formula I, wherein the groups R1, R2 and m are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
INDANYLOXYPHENYLCYCLOPROPANECARBOXYLIC ACIDS
-
Paragraph 0567, (2014/01/07)
The present invention relates to compounds of general formula I, wherein the groups R1, R2, R3, m and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.